Search Results
Jan 06, 2026, 09:15 ET Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis
IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Jan 06, 2026, 09:00 ET BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East
patient reluctance to undergo invasive procedures. To overcome these barriers, the investigators adopted plasma-based liquid biopsy using cell-free DNA (cfDNA) genomic analysis as a non-invasive alternative to tissue-based genomic testing.With sensitivity as a critical performance metric, investigators
More news about: BillionToOne
Jan 06, 2026, 08:00 ET Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals, collaborate on Genetic Medicines Project with support from UKRI Innovate UK and Canadian R&D Funding
Together, the companies aim to provide cell-type selective, durable DNA-based gene expression cargo with safe and effective, intracellular fusion-based delivery. The combined innovative technology could be applied to treat
More news about: CHROMATIN BIOSCIENCE LTD
Jan 06, 2026, 08:00 ET Freenome Delivers Improved Performance in Its Colorectal Cancer Blood Test with Sensitivity of 85% for CRC and 22% for Advanced Precancerous Lesions
SimpleScreen CRC was built using this platform and applies an AI/ML-based model to detect specific methylation signatures in tumor-derived cell-free DNA (cfDNA) at single-base resolution.Freenome has also been working on upgrades to the AI/ML learning algorithm; these improvements will be described
More news about: Freenome Holdings, Inc.
Jan 06, 2026, 07:37 ET EdgeLabs Officially Enters the European Market Through Strategic Partnership with SpinOro
"We're thrilled to take our relationship with SpinOro to the next level. At our core, both companies are builders of great games; that shared DNA makes this partnership incredibly natural and exciting. Together we'll bring best-in-class content, enhanced promotional tools, custom game development,
More news about: EdgeLabs
Jan 06, 2026, 03:30 ET LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington's Disease
HD. DNA mismatch repair has been shown as a key driver of HD and other triplet repeat diseases. Convergent evidence from human genetics, post-mortem studies, and mechanistic research identifies MSH3/MutSβ as the most promising target of the DNA mismatch repair pathway. However,
More news about: LoQus23 Therapeutics
Jan 05, 2026, 11:15 ET GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
Kong, China, GenEditBio is a clinical-stage gene therapy startup with a strategic goal of providing in vivo genome-editing therapeutic solutions (dubbed "DNA surgery") that are fundamentally safe, precise, efficacious, and affordable for genetic diseases with unmet needs. The Company's core areas of focus
More news about: GenEditBio Limited
Jan 05, 2026, 09:00 ET Eliza and Kickdrum Join Forces to Launch OpenAI Technical Training Academy
team for nearly five years, this was the perfect opportunity to combine our strengths and bring a true partnership to life," said Kennedy. "Kickdrum's DNA is rooted in solving complex software challenges while deliberately investing in the next generation of technologists. Together, we are creating a program
More news about: Eliza
Jan 05, 2026, 09:00 ET Rare Beauty by Selena Gomez to Launch Nationwide in Ulta Beauty
and Chief Executive Officer, Ulta Beauty. "Supporting and giving back to our community through the Ulta Beauty Charitable Foundation is core to our DNA and reaffirms our commitment to using beauty as a force for good. To team up with Selena and Rare to authentically deliver on our values and drive impact
More news about: Rare Beauty
Jan 05, 2026, 08:01 ET MONSTER ENERGY INTRODUCES MONSTER ENERGY STRAWBERRY SHOT
bold and refreshing new way to enjoy the legendary OG Monster flavor, now with an added shot of strawberry that pumps up the taste without changing the DNA fans know and love.
More news about: Monster Energy
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Kelun-Biotech
Jan 05, 2026, 03:15 ET GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
Kong, China, GenEditBio is a clinical-stage gene therapy startup with a strategic goal of providing in vivo genome-editing therapeutic solutions (dubbed "DNA surgery") that are fundamentally safe, precise, efficacious, and affordable for genetic diseases with unmet needs. For more information, please visit
More news about: GenEditBio Limited
Jan 04, 2026, 23:02 ET 引正基因首個體內基因組編輯藥物GEB-101獲得FDA新藥臨床試驗批准 用於治療TGFBI相關眼角膜營養不良
基因中的特定位置，並由公司自主開發的工程化蛋白遞送載體（PDV）實現精準體內遞送。GEB-101正在研究者發起的臨床試驗中進行安全性和初步有效性評估。關於引正基因GenEditBio引正基因成立於 2021 年，總部位於中國香港，是一家臨床階段的基因治療初創公司，致力於提供安全、精準、有效和可負擔的體內基因組編輯治療解決方案（簡稱「DNA 手術」），以填補臨床醫治未能滿足的需求。公司的核心研發領域包括新型 Cas 核酸酶基因組編輯器的開發，以及利用脂質納米顆粒（LNP）與工程化蛋白遞送載體（PDV）實現安全和高效的體內遞送。公司在香港、北京和波士頓設有研究實驗室和辦公室。引正基因由頂級生命科學投資者資助，包括啟明創投、方圓資本、晟德藥業、順天醫藥、香港科技園創投基金等。如要更多資訊，請到訪公司網頁
More news about: GenEditBio Limited
Jan 04, 2026, 09:00 ET Zeroth Robotics Launches into the U.S. with Debut Lineup of Interactive AI Robots for Consumer and Commercial Buyers
execution, combining autonomous mobility with remote operation. Zeroth's Technology DNABeyond its first product, M1, Zeroth is building a multi-robot future on what it calls its Technology DNA – a unified stack that will power all forthcoming consumer and commercial robots. This foundation
More news about: Zeroth
Dec 31, 2025, 07:25 ET Smart Oncology: 5 Stocks Chasing the $317B Prize
tumors."The NeXT Personal test tracks up to 1,800 tumor-specific variants unique to each patient, achieving ultrasensitive detection of circulating tumor DNA. Patients with decreasing ctDNA levels early in treatment had significantly higher overall survival, while those with increasing ctDNA had a zero percent
More news about: USA News Group
Dec 31, 2025, 02:48 ET HZICC: Hangzhou and the World: 10 Paired Conversations
restoring people's diet and life by measuring the stable isotope ratios of human bodies. The two scholars not only discussed the possibility of ancient DNA technology in the research of Liangzhu Civilization, but also explored the methodological innovation and theoretical breakthrough of archaeological science
More news about: HZICC
Dec 30, 2025, 23:02 ET Nootropics Depot Calls for Shift to Bioactive Standardization in Botanicals
New white paper releaseThe white paper examines systemic issues such as overreliance on DNA barcoding, macroscopic and chromatographic identification, and the marketing of high-ratio extracts that are not supported by compound-level data. Using
More news about: Nootropics Depot
Dec 30, 2025, 10:28 ET Urielle si predstavuje svetlú budúcnosť
„Rozprávanie príbehov je moja vášeň. Viem, že cesta je dlhá a potrvá ešte minimálne šesť rokov, kým budem môcť ísť na univerzitu. Ale aj tak, jedného dňa budem mať vlastnú rozhlasovú reláciu!"Jej ambície nepoznajú hraníc – a jej úspechy sú dôkazom potenciálu všetkých detí, keď majú prístup k vzdelaniu,
More news about: Education Cannot Wait
Dec 30, 2025, 10:10 ET The Skin of Color Society (SOCS) Reports an Impactful Year of Progress, Expansion, and Innovation Toward Advancing Knowledge and Excellence in Patient Care
University Department of Dermatology.2nd Place: Shahin Shahsavari, BA, Geisel School of Medicine at Dartmouth, "Investigating DNA Methylation in Prurigo Nodularis: Racial Variations in Epigenetic Neuroregulation."3rd Place: Swathi Holla, MS, Baylor College
More news about: Skin of Color Society
Dec 30, 2025, 10:00 ET Yellow Meets Yellow: Parimatch Joins Forces with Joburg Super Kings as Official Principal Partner
debut season and earning a reputation for thrilling last-over finishes and a passionate fan following. Known for the iconic yellow jerseys and a winning DNA, the team also draws inspiration and strategy from the IPL parent franchise, Chennai Super Kings.Parimatch, a brand that partners with top teams
More news about: Parimatch
Dec 30, 2025, 09:01 ET PAVmed Announces Reverse Stock Split
Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer
More news about: PAVmed Inc.
Dec 30, 2025, 09:00 ET Co-Diagnostics Announces Reverse Stock Split
diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to
More news about: Co-Diagnostics
Dec 29, 2025, 09:00 ET Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to
More news about: Co-Diagnostics
Dec 29, 2025, 08:14 ET Disrupting FinTech: Jayesh Kumar Replaces Broken Banking Stacks with AI Agentic Orchestration
solutions that fit the client's unique current state."To truly disrupt, we meet clients where they are," says Kumar. "We replicate the company's DNA on our platform so that when they are ready for a no-code solution, our tool is the only one that fits their specific use case because it already contains
More news about: Disruption Interruption
Dec 29, 2025, 08:05 ET FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
medicines.About INOVIO's DNA Medicines PlatformINOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are
More news about: INOVIO Pharmaceuticals, Inc.